



## BREAST CANCER (FEBRUARY 2016): MOLECULAR ONCOLOGY TUMOR BOARDS COURSE REFERENCES

Collins LC, Cole KS, Marotti JD, et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. *Mod Pathol.* 2011; 24:924-931. ([Full Text](#))

Doane AS, Danso M, Lal P, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. *Oncogene.* 2006; 25:3994-4008. ([Full Text](#))

Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. *Oncogene.* 2005; 24:4660-4671. ([Full Text](#))

Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. *Clin Cancer Res.* 2013; 19:5505-5512. ([Full Text](#))

Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. *Cancer Discov.* 2013; 3(9):1020-1029. ([Full Text](#))

Korpai M, Korn JM, Gao X, et al. An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide). *Cancer Discov.* 2013; 3(9):1030-1043. ([Full Text](#))

Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest.* 2011; 121(7):2750-2767. ([Full Text](#))

National Comprehensive Cancer Network. Breast and/or Ovarian Genetic Assessment NCCN Guidelines. Accessed February 2, 2016. ([View Guidelines](#))

Ni M, Chen Y, Lim E, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. *Cancer Cell.* 2011; 20(1):119-31. ([Full Text](#))

Niemeier LA, Dabbs DJ, Beriwal S, et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. *Mod Pathol.* 2010; 23(2):205-212. ([Full Text](#))

Robinson JL, Macarthur S, Ross-Innes CS, et al. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. *EMBO J.* 2011; 30(15):3019-3027. ([Full Text](#))

Rugo HS, Barry WT, Moreno-Aspitia A, et al. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). *J Clin*

*Oncol.* 2015 Jul 20;33(21):2361-9. ([Full Text](#))

Seidman AD, Conlin AK, Bach A, et al. Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer. *Clin Breast Cancer.* 2013 Aug;13(4):239-246.e1. ([Full Text](#))

Traina TA, O'Shaughnessy J, Nanda R, et al. Stage 1 results from a 2-stage study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). Poster session P5-19-09 presented at: 37<sup>th</sup> Annual San Antonio Breast Cancer Symposium; 2014 Dec 12; San Antonio, TX. ([View Poster](#))

Tutt A, Ellis P, Kilburn L, et al. TNT: A Randomized Phase III Trial of Carboplatin compared with Docetaxel for Patients with Metastatic or Recurrent Locally Advanced Triple Negative or BRCA 1/2 Breast Cancer. Abstract presented at: 2014 San Antonio Breast Cancer Symposium. 2014 Dec 11; San Antonio, Texas. ([View Abstract](#))